These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 28192104)
1. Practical Use of Pharmacotherapy for Obesity. Igel LI; Kumar RB; Saunders KH; Aronne LJ Gastroenterology; 2017 May; 152(7):1765-1779. PubMed ID: 28192104 [TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy for obesity: What you need to know. Bersoux S; Byun TH; Chaliki SS; Poole KG Cleve Clin J Med; 2017 Dec; 84(12):951-958. PubMed ID: 29244650 [TBL] [Abstract][Full Text] [Related]
4. Current and emerging pharmacotherapies for obesity in Australia. Hocking S; Dear A; Cowley MA Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558 [TBL] [Abstract][Full Text] [Related]
5. Obesity Epidemic: Pharmaceutical Weight Loss. Curry SA R I Med J (2013); 2017 Mar; 100(2):18-20. PubMed ID: 28246654 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird. Rubio MA Endocrinol Nutr; 2014 Dec; 61(10):501-4. PubMed ID: 25434595 [No Abstract] [Full Text] [Related]
8. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618 [TBL] [Abstract][Full Text] [Related]
9. Overview of new antiobesity drugs. Hainer V Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293 [TBL] [Abstract][Full Text] [Related]
10. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain. Howland RH J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546 [TBL] [Abstract][Full Text] [Related]
11. A Comparison of New Pharmacological Agents for the Treatment of Obesity. Nuffer W; Trujillo JM; Megyeri J Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340 [TBL] [Abstract][Full Text] [Related]
12. Recent advancements in drug treatment of obesity. Carter R; Mouralidarane A; Ray S; Soeda J; Oben J Clin Med (Lond); 2012 Oct; 12(5):456-60. PubMed ID: 23101148 [TBL] [Abstract][Full Text] [Related]
13. Drug treatment of obesity: current status and future prospects. Kakkar AK; Dahiya N Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851 [TBL] [Abstract][Full Text] [Related]
14. Review of pharmacotherapy options for the management of obesity. Bragg R; Crannage E J Am Assoc Nurse Pract; 2016 Feb; 28(2):107-15. PubMed ID: 26119641 [TBL] [Abstract][Full Text] [Related]
15. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. Halpern B; Mancini MC Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121 [TBL] [Abstract][Full Text] [Related]
19. Nonincretin drugs in later-stage development. Zimmerman MP; Mehr SR Am J Manag Care; 2014 Jan; 20(1 Spec No.):E2. PubMed ID: 25618226 [No Abstract] [Full Text] [Related]
20. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Tak YJ; Lee SY Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]